Resonance Health Ltd (RHT) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Resonance Health Ltd stock A$0.09, price A$0.08, upside +14.5%, quality 66 out of 100. Rating: undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range A$0.0330 – A$0.2000 · fair‑value band A$0.0639 – A$0.1101 · the A$0.0760 price screens below the A$0.0870 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Resonance Health in your weekly email
Every Wednesday you see whether Resonance Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa.
Show moreShow less
It operates through SaMD, Resonance Clinical, and TrialsWest segments.
The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report; and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading.
It also provides phantoms comprising FerriScan, R2*/T2*, T1CMR, and T2CMR phantoms for the calibration of MRI machines.
In addition, the company operates as an imaging contract research organization that provides comprehensive proposal and project management support, site set-up, imaging charter development, clinical reports, data transfer agreements, and compliance services for clinical trial sponsors.
It serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
Stock analysis
Resonance Health Ltd (RHT) currently trades at A$0.0760, while our model-based Fair Value estimate is A$0.0870, implying the stock looks roughly 13% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of A$0.1350 per share, and 13 of the 23 models we run sit above the A$0.0760 price.
Bear case: the Economic Profit group reads lowest at A$0.0400, and 10 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: A$0.0639 (bear) to A$0.1101 (bull), the price of A$0.0760 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Resonance Health Ltd reported revenue of A$15.8M in FY2026 versus A$3.8M in FY2022, a compound +42.4%/yr. Reported net income was A$1.5M in FY2026.
Key figures
Market cap A$36.2M (≈ $25.0M) Micro · P/S ratio 2.24 · Net margin 9.6% · Return on equity 14.8% · Return on assets (EBIT) −7.4% (5-year average) · Operating margin 7.7% · Revenue (TTM) A$15.8M · Revenue growth (YoY) +32.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 111% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at 14%, RHT screens cheaper than that median.
Fair Value models
BearA$0.0639Fair Value A$0.0870BullA$0.1101
Price A$0.0760 · Upside +14.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.87/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+42.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.0%
Start year 2021 (pandemic). Over 10 years: +20.0% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+19.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.19.6% vs 10.6%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 10%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about −1.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Above median
Fair Value upside+14.5% · Top 25%
Profitability
Return on equity (12 months)14.8% · Top 25%
Return on assets8.1% · Top 25%
Net margin (12 months)9.6% · Above median
Operating margin (12 months)7.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)32.7% · Top 25%
Balance sheet
Debt / equity0.23× · Highest 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B3.26× · Pricier than median
P/S (12 months)2.30× · Cheaper than median
Price / free cash flow (fiscal year)13.0× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Resonance Health Ltd Fair Value". https://www.fairvalue-calculator.com/stock/RHT
Frequently asked questions
Is Resonance Health Ltd (RHT) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of A$0.0870 versus a price of A$0.0760, about +14% upside (undervalued).
What is the fair value of RHT?
Our model-based fair value for Resonance Health Ltd is A$0.0870 (as of Nov 7, 2026), built from audited fundamentals. The current price: A$0.0760.
What is the quality score of RHT?
Resonance Health Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Resonance Health Ltd (RHT)?
Our model-based price target is the fair value of A$0.0870 (as of Nov 7, 2026) from 23 valuation models. Cautious scenario A$0.0639, optimistic scenario A$0.1101. It is a calculation from audited fundamentals, not an analyst target.
What is the Resonance Health Ltd stock forecast for 2026?
Our models put fair value at A$0.0870, about +14% upside versus a price of A$0.0760 (undervalued). Cautious scenario A$0.0639, optimistic scenario A$0.1101. The calculation is refreshed regularly with new filings.
What is the revenue of Resonance Health Ltd (RHT)?
Resonance Health Ltd reported trailing-twelve-month revenue of about A$15.8M (latest available figure, as of Nov 7, 2026).
What growth is priced into Resonance Health Ltd (RHT)?
For today's price to be fair in a discounted-cash-flow model, Resonance Health Ltd would have to grow free cash flow by +1.3 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +33.0 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of RHT use?
Our models discount Resonance Health Ltd at 9.5 %: a base by market capitalisation (nano), damped by beta 1.01, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Resonance Health Ltd that is +1.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Resonance Health Ltd (RHT) delivered so far?
Over the past 5 years revenue at Resonance Health Ltd grew +33.0 % a year. The price currently implies free-cash-flow growth of +1.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Resonance Health Ltd (RHT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Resonance Health Ltd (+1.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Resonance Health Ltd (RHT)?
The free-cash-flow yield on the price is 7.70 %: that much free cash flow Resonance Health Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Resonance Health Ltd (RHT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Resonance Health Ltd it is A$0.0870 per share (as of Nov 7, 2026), against a price of A$0.0760. It is the blended result of 23 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Resonance Health Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, RHT trades below its calculated fair value: price A$0.0760, fair value A$0.0870, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RHT?
No. The price is what the market pays today (A$0.0760); the fair value is what the company's own numbers justify (A$0.0870). For Resonance Health Ltd the two are A$0.0110 per share apart. That gap is exactly why we show both numbers side by side.
How much is Resonance Health Ltd worth?
The market values Resonance Health Ltd at about A$36.2M (market capitalisation, as of Nov 7, 2026). Per share that is A$0.0760; our models calculate a fair value of A$0.0870 per share.
What do the bullish and bearish scenarios say about RHT?
Our models span a range for Resonance Health Ltd: cautious scenario A$0.0639, base A$0.0870, optimistic A$0.1101 per share (as of Nov 7, 2026, price A$0.0760). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of RHT?
The PEG ratio of Resonance Health Ltd is 2.55 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Resonance Health Ltd (RHT)?
Balance-sheet figures for Resonance Health Ltd (as of Nov 7, 2026): return on equity 14.8%, debt of 0.23 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is RHT from its 52-week high?
Resonance Health Ltd trades at A$0.0760, about 12% below its 52-week high of A$0.0860 and 111% above the low of A$0.0360 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0870 is for.
Which stocks are comparable to Resonance Health Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Resonance Health Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price A$0.0760, calculated fair value A$0.0870 (+14%), Quality Score 66/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RHT calculated?
We run Resonance Health Ltd through 23 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$0.0870 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Resonance Health Ltd currently trades 13% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Resonance Health Ltd (RHT)?
The closing price on Nov 9, 2026 was A$0.0760. Our model-based fair value is A$0.0870, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Resonance Health Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Resonance Health Ltd
How large is the market capitalisation of Resonance Health Ltd (RHT)?
The market capitalisation of Resonance Health Ltd is A$36.2M (≈ $25.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Resonance Health Ltd (RHT)?
The price-to-sales ratio of Resonance Health Ltd is 2.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Resonance Health Ltd (RHT)?
The net margin of Resonance Health Ltd is 9.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Resonance Health Ltd (RHT)?
The return on equity (ROE) of Resonance Health Ltd is 14.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Resonance Health Ltd (RHT)?
On an EBIT basis the return on assets of Resonance Health Ltd is −7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Resonance Health Ltd (RHT)?
The operating margin of Resonance Health Ltd is 7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Resonance Health Ltd (RHT)?
Revenue at Resonance Health Ltd is growing +32.7% versus a year earlier (3y avg +52.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Resonance Health Ltd (RHT)?
Earnings per share at Resonance Health Ltd are growing +5.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Resonance Health Ltd (RHT) hold?
Resonance Health Ltd holds more cash than debt, A$1.0M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Resonance Health Ltd in the live analysis
One click puts Resonance Health Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026